Previous 10 | Next 10 |
Transformative Initiative Expected to Accelerate Development of CH5126766 (VS-6766), a RAF/MEK Inhibitor, in Combination with Defactinib, a FAK Inhibitor, for the Treatment of KRAS Mutant Solid Tumors Company Continues to Advance Development of Duvelisib for the Treatment of Relapsed/R...
Verastem, Inc. (NASDAQ: VSTM) (the “Company”), today announced that it has agreed to sell approximately 46.5 million shares of its common stock to certain institutional investors, including RA Capital Management, Vivo Capital, Venrock Healthcare Capital Partners, Farallon Capita...
My cancer scare changed my life. I’m grateful for every new, healthy day I have. It has helped me prioritize my life. - Olivia Newton-John Verastem ( VSTM ) has been burdened by very high R&D and SGA costs, a long drug development cycle, low turnover, and an almost-eroded ne...
Those interested in holding Verastem (VSTM) should first ask themselves the two following questions. First question, what do you see as the future of oncology generally? Is the future in pinpoint chemical disruption of tumor growth, through whatever biochemical pathway it might be? Or is it in...
Verastem, Inc. ( VSTM ) had a rough 2019 with a disappointing launch for COPIKTRA and the share price reacted accordingly. Recently, the company publicized that they closed a global licensing agreement with Chugai Pharmaceutical ( CHGCF ) to acquire the worldwide development and commercializ...
4 Penny Stocks To Watch This Week Let’s call it what it is everyone, coronavirus scared the market into buying anything remotely related to vaccines or respiratory protection. We saw facemask companies skyrocket, cancer stocks turn into coronavirus plays and everything in between. Nee...
Verastem (NASDAQ: VSTM ) is up 3.7% after hours following an ownership filing by Point72. More news on: Verastem, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Deals and Financings Sorrento Therapeutics (SRNE), a San Diego-Nanjing-Suzhou biopharma, rejected a $7 per share take-private offer from an unnamed PE company that valued the company at $933 million. Sorrento, which is facing a cash crunch, reported a loss of $57 million over the last 12...
Verastem, Inc. (Nasdaq: VSTM), (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced that its partner CSPC Pharmaceutical Group Limited (HKEx: ...
5 Penny Stocks On Robinhood To Watch This Month Investing in penny stock can often prove to be the most rewarding class of stocks for investors. Why? Over the years, these stocks have generated a lot of wealth for investors, quickly. One of the most important things that need to be pointed o...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States Sangamo Therapeutics Inc. (SGMO) rose 50.7% to $0.604699 on volume of 90,844,210 shares Selina Hospitality PLC (SLNA) rose 7.7% to $0.028 on volume of 57,431,570 shares NuZee Inc. (NUZE) rose 260.1% to $3.7094 on volume of 53,639,595 ...
Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the pricing of an underwritten public offering of 13,333,334 shares of its common stock and accompanying warrants to purchase up to 13,333,334 shares of it...
Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of common stock, as well as pre-funded warrants t...